Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

389 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.
Loftus EV Jr, Colombel JF, Takeuchi K, Gao X, Panaccione R, Danese S, Dubinsky M, Schreiber S, Ilo D, Finney-Hayward T, Zhou W, Phillips C, Gonzalez YS, Shu L, Yao X, Zhou Q, Vermeire S. Loftus EV Jr, et al. Clin Gastroenterol Hepatol. 2022 Dec 1:S1542-3565(22)01109-0. doi: 10.1016/j.cgh.2022.11.029. Online ahead of print. Clin Gastroenterol Hepatol. 2022. PMID: 36464141
Interobserver Agreement of Modified Paris Classification and Histology Prediction of Colorectal Lesions in Patients with Inflammatory Bowel Disease.
Vinsard DG, Br Uining DH, East JE, Ebner D, Kane SV, Kisiel JB, Leighton JA, Lennon RJ, Loftus EV Jr, Malik T, Picco M, Raffals L, Ramos GP, Santiago P, Coelho-Prabhu N. Vinsard DG, et al. Among authors: loftus ev jr. Gastrointest Endosc. 2022 Nov 16:S0016-5107(22)02156-3. doi: 10.1016/j.gie.2022.11.006. Online ahead of print. Gastrointest Endosc. 2022. PMID: 36402202
Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.
Peyrin-Biroulet L, Ghosh S, Lee SD, Lee WJ, Griffith J, Wallace K, Berg S, Liao X, Panes J, Loftus EV Jr, Louis E. Peyrin-Biroulet L, et al. Among authors: loftus ev jr. Aliment Pharmacol Ther. 2022 Oct 20. doi: 10.1111/apt.17242. Online ahead of print. Aliment Pharmacol Ther. 2022. PMID: 36266762
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium.
Johnson AM, Barsky M, Ahmed W, Zullow S, Galati J, Jairath V, Narula N, Peerani F, Click BH, Coburn ES, Dang TT, Gold S, Agrawal M, Garg R, Aggarwal M, Mohammad D, Halloran B, Kochhar GS, Todorowski H, Ud Din NM, Izanec J, Teeple A, Gasink C, Muser E, Ding Z, Swaminath A, Lakhani K, Hogan D, Datta S, Ungaro RC, Boland BS, Bohm M, Fischer M, Sagi S, Afzali A, Ullman T, Lawlor G, Baumgart DC, Chang S, Hudesman D, Lukin D, Scherl EJ, Colombel JF, Sands BE, Siegel CA, Regueiro M, Sandborn WJ, Bruining D, Kane S, Loftus EV Jr, Dulai PS. Johnson AM, et al. Among authors: loftus ev jr. Am J Gastroenterol. 2022 Nov 23. doi: 10.14309/ajg.0000000000002047. Online ahead of print. Am J Gastroenterol. 2022. PMID: 36191274
Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial.
Danese S, Ferrante M, Feagan BG, Peyrin-Biroulet L, Hibi T, Sandborn WJ, Schreiber S, Ritter T, Loftus EV Jr, Rogler G, Oortwijn A, Yun C, Le Brun FO, Dinoso J, Hsieh J, Vermeire S. Danese S, et al. Among authors: loftus ev jr. Am J Gastroenterol. 2022 Nov 11. doi: 10.14309/ajg.0000000000001979. Online ahead of print. Am J Gastroenterol. 2022. PMID: 36113491
The Global Incidence of Peptic Ulcer Disease Is Decreasing Since the Turn of the 21st Century: A Study of the Organisation for Economic Co-Operation and Development (OECD).
Azhari H, King JA, Coward S, Windsor JW, Ma C, Shah SC, Ng SC, Mak JWY, Kotze PG, Ben-Horin S, Loftus EV Jr, Lees CW, Gearry R, Burisch J, Lakatos PL, Calvet X, Bosques Padilla FJ, Underwood FE, Kaplan GG. Azhari H, et al. Among authors: loftus ev jr. Am J Gastroenterol. 2022 Sep 1;117(9):1419-1427. doi: 10.14309/ajg.0000000000001843. Epub 2022 Jun 2. Am J Gastroenterol. 2022. PMID: 35973143
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group. Sands BE, et al. Among authors: loftus ev jr. Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2. Lancet. 2022. PMID: 35691323 Clinical Trial.
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, Hébuterne X, D'Haens G, Nakase H, Panés J, Higgins PDR, Juillerat P, Lindsay JO, Loftus EV Jr, Sandborn WJ, Reinisch W, Chen MH, Sanchez Gonzalez Y, Huang B, Xie W, Liu J, Weinreich MA, Panaccione R. Danese S, et al. Among authors: loftus ev jr. Lancet. 2022 Jun 4;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5. Epub 2022 May 26. Lancet. 2022. PMID: 35644166 Clinical Trial.
389 results